Beam Therapeutics
BEAM
246 hedge funds and large institutions have $2.96B invested in Beam Therapeutics in 2025 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 78 increasing their positions, 62 reducing their positions, and 31 closing their positions.
1,048% more call options, than puts
Call options by funds: $69.9M | Put options by funds: $6.08M
106% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 31
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
26% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 62
15% more capital invested
Capital invested by funds: $2.59B → $2.96B (+$376M)
13% more funds holding
Funds holding: 218 → 246 (+28)
0.05% less ownership
Funds ownership: 105.36% → 105.31% (-0.05%)
Top Buyers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$36.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$31.1M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$24.1M |
| 4 |
Two Sigma Investments
New York
|
+$18.9M |
| 5 |
RI
RTW Investments
New York
|
+$14.6M |
Top Sellers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$70.9M |
| 2 |
CGH
Contrarius Group Holdings
Hamilton,
Bermuda
|
-$37.2M |
| 3 |
Goldman Sachs
New York
|
-$20.3M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$19.6M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$10.8M |
BEAM Hedge Fund Activity: Q4 2025 in Review
246 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q4 2025, worth a combined $2.96B — up 15% from $2.59B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new BEAM positions and 31 closed out — a net gain of 33 holders — while 78 added to existing stakes and 62 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $36.4M. The largest seller was Bellevue Group, cutting an estimated $70.9M.
- 246 institutional investors held Beam Therapeutics (BEAM) as of Q4 2025, up from 218 in Q3 2025.
- Funds reported $2.96B of Beam Therapeutics stock for Q4 2025, up 15% quarter-over-quarter.
- 64 funds opened new Beam Therapeutics positions in Q4 2025 and 31 closed out, a net change of +33 holders.
- The largest Beam Therapeutics buyer in Q4 2025 was ARK Investment Management, an estimated $36.4M added.
- The largest Beam Therapeutics seller in Q4 2025 was Bellevue Group, an estimated $70.9M sold.
Based on aggregated 13F filings for Q4 2025.